Healthcare Industry News: Anti-Bacterial Envelope
News Release - March 4, 2009
TYRX Announces the Appointment of Gail O'Brien Turner as Vice President, SalesMONMOUTH, NJ--(Healthcare Sales & Marketing Network)--Mar 4, 2009 -- TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, today announced that it has appointed Gail O'Brien Turner as Vice President, Sales.
Ms. Turner brings to TYRX over 25 years of sales and management experience in the medical device space through her numerous positions of increasing responsibility with Guidant, now part of Boston Scientific. Most recently, Ms. Turner held the role of Area Vice President of Sales, CRMD, where she had responsibility for the Northeast and managed 135 field personnel and was accountable for revenue of $300 million. Ms. Turner began her career with IVAC, successfully selling infusion devices and vital signs monitoring equipment, and then moved to the Interventional Cardiology market (ACS), where she was equally successful in selling angioplasty catheters and launching the Multi-Link Stent. Her last role within Guidant was to manage the Leadership Development effort across all business units, where she was responsible for identifying and developing key managerial talent for the organization. Ms. Turner has been recognized and named "Rising Star" by the Healthcare Businesswoman Association, a national award that recognizes achievement and excellence in leadership. Ms. Turner earned a BS degree in Economics from Boston College.
"Gail brings to TYRX a unique blend of sales skills, sales management experience, and personnel development," remarked William Edelman, President and CEO for TYRX. Mr. Edelman continued, "Gail's experience in the Cardiac Rhythm Management space, as well as her demonstrated track record of leading successful sales organizations, will contribute greatly to the ongoing commercialization of the AIGISRx Anti-Bacterial Envelope in the implantable medical device market."
Ms. Turner remarked, "I am thrilled to be at TYRX. I view this as a tremendous opportunity, in light of the increasing awareness and impact of surgery acquired infections related to device implants. It is my belief that the AIGISRx product is the most effective approach in reducing these life threatening and costly complications. It will set a new standard in patient care."
About TYRX, Inc.
TYRX, Inc., an ISO 9001:2000 and ISO 13485:2003 certified medical device manufacturer, commercializes implantable combination drug/device products, including the AIGISRx(TM) Anti-Bacterial Envelope. AIGISRx contains the antimicrobial agents, rifampin and minocycline, which have been shown to reduce infection by organisms representing a majority of the infections reported in cardiac rhythm device related endocarditis, including "superbugs" or MRSA. In addition, AIGISRx is intended to securely hold a pacemaker or implantable cardioverter defibrillator (ICD) in order to create a stable environment when implanted in the body. Following commercial release in June, 2008, AIGISRx has been implanted in over 2,200 patients nationwide. In February, 2008 TYRX raised $25 million in a venture capital financing led by Clarus Ventures and co-led by Pappas Ventures. TYRX products utilize novel biomaterials, including technology licensed exclusively from Rutgers, The State University of New Jersey. Additionally, TYRX has exclusively licensed from Baylor College of Medicine and The University of Texas M. D. Anderson Cancer Center product patents and associated technologies to address the problem of postsurgical nosocomial infection. TYRX is deploying its capabilities across a broad range of combination implantable medical-pharmaceutical devices. The combination products sector (products incorporating both a drug & a device component) is expected to be the highest growth segment of the medical products industry and TYRX is positioned to be an innovative applications leader in the space.
For more information, please visit www.TYRX.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.